David Nicholas Gee Sells 2,198 Shares of Cellebrite DI (NASDAQ:CLBT) Stock

Cellebrite DI Ltd. (NASDAQ:CLBT) CMO David Nicholas Gee sold 2,198 shares of the business’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $11.24, for a total transaction of $24,705.52. Following the completion of the sale, the chief marketing officer owned 139,604 shares of the company’s stock, valued at approximately $1,569,148.96. The trade was a 1.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

David Nicholas Gee also recently made the following trade(s):

• On Wednesday, August 12th, David Nicholas Gee sold 230 shares of Cellebrite DI stock. The stock was sold at an average price of $16.07, for a total transaction of $3,696.10.

Cellebrite DI Trading Up 4.0%

Shares of CLBT traded up $0.44 during mid-day trading on Monday, reaching $11.49. The company had a trading volume of 3,463,245 shares, compared to its average volume of 2,270,829. The stock has a market cap of $2.87 billion, a price-to-earnings ratio of 52.23, a price-to-earnings-growth ratio of 1.53 and a beta of 1.18. The firm has a fifty day simple moving average of $14.27 and a 200-day simple moving average of $13.85. Cellebrite DI Ltd. has a fifty-two week low of $9.58 and a fifty-two week high of $19.98.

Institutional Trading of Cellebrite DI

A number of institutional investors and hedge funds have recently modified their holdings of the business. Towarzystwo Funduszy Inwestycyjnych PZU SA boosted its stake in Cellebrite DI by 81.0% in the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock valued at $34,000 after acquiring an additional 850 shares during the period. Advisory Services Network LLC bought a new stake in shares of Cellebrite DI during the 3rd quarter worth about $40,000. CWM LLC increased its position in shares of Cellebrite DI by 57.0% during the 4th quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $44,000 after purchasing an additional 889 shares during the period. Elevation Wealth Partners LLC acquired a new position in shares of Cellebrite DI in the 2nd quarter worth approximately $44,000. Finally, Vestcor Inc bought a new position in shares of Cellebrite DI in the third quarter valued at $70,000. 45.88% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have commented on CLBT shares. DA Davidson dropped their price target on Cellebrite DI from $22.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, August 14th. JPMorgan Chase & Co. reduced their price target on shares of Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating on the stock in a research report on Friday, August 14th. Weiss Ratings lowered shares of Cellebrite DI from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, August 13th. Lake Street Capital decreased their price target on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Finally, Needham & Company LLC reduced their target price on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating on the stock in a research report on Friday, August 14th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $16.70.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.